Why Novo Nordisk has moved Delhi HC against Sun Pharma
What's the story
Novo Nordisk, the Danish pharmaceutical giant and the original developer of semaglutide, has filed a lawsuit against Sun Pharma in the Delhi High Court. The move comes as part of its strategy to prevent Indian companies from launching generic versions of this highly successful diabetes and weight loss drug. The case was heard briefly by Justice Tejas Karia, who transferred it to another bench already hearing similar cases against Dr Reddy's Laboratories and Natco Pharma.
Court proceedings
Novo seeks assurance from Sun Pharma
During the court hearing, Novo's counsel urged Sun Pharma to give an assurance that it wouldn't launch its generic version of semaglutide within 24 hours. The request was made in light of the company's plea for urgent interim relief against any such launch. This comes after Justice Arora had earlier allowed Dr Reddy's Laboratories to export semaglutide to non-patent countries until March 2026, while restricting domestic sales until patent expiry.
Future plans
Novo plans to appeal against court's ruling
Novo's counsel indicated the company intends to appeal against the ruling next week before a division bench. This comes after Justice Arora had denied an interim injunction against Dr Reddy's Labs. The court had said that Novo hadn't made a strong enough case for an interim ban, and added that any financial losses could be compensated later.
Drug development
Semaglutide's journey and market competition
Semaglutide, the active ingredient in Novo's GLP-1 drugs (Ozempic, Wegovy, and Rybelsus), was initially developed for type-2 diabetes but later approved for obesity treatment. Clinical studies showed 15-23% weight loss with its use. In India, Wegovy was launched in June at a monthly cost of ₹17,345-₹26,050. However, it was later reduced by 37% to ₹10,850 amid growing competition from Cipla and Emcure Pharma, who have partnered with Eli Lilly and Novo Nordisk respectively to distribute their drugs domestically.